Aitia, a US-based company involved in computationally discovering and applying new knowledge of biological causes of disease to pharmaceutical discovery and development, announced on Wednesday a partnership with Gustave Roussy, a cancer research institute in Europe.

The new partners say that they will collaborate to transform Gustave Roussy's extensive cancer patient data into human 'Gemini Digital Twins' -- computer-based in silico models that reveal the hidden underlying causes of complex diseases like cancer to drive the discovery and clinical development of effective new therapies.

"If we identify the specific cancer-causing changes buried in the massively complex biology that leads to diseases like cancer, we can also identify a clear path to the 'next generation' of effective therapeutic interventions," said Colin Hill, Aitia CEO and co-founder. "Informed by Gustave Roussy's extensive database of de-identified human multiomic and patient outcome data, our causal AI discovery engine and the Gemini Digital Twins it builds, reveals the fundamental knowledge needed for successful drug discovery and clinical development."

"Gustave Roussy is excited to work with Aitia to realise our shared mission of accelerating and applying new knowledge of cancer biology to its successful treatment," said Prof. Fabrice Barlesi, Gustave Roussy CEO. "Aitia's ability to accurately model complex biological systems from de-identified human multiomic and patient outcome data should give us a significant advantage in the battle against these devastating diseases and bring renewed hope to cancer patients and their families worldwide."